LAURUSLABS

Laurus Labs Limited

APIs and CDMO work, rooted in HIV generics and affordable medicines

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

lauruslabs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹2060.10
Market cap
1,11,203 Cr
Stock P/E
101.7
P/B
20.99
Dividend yield
0.1%
ROE (FY26)
16.4%
ROCE (FY26)
17.3%
Operating margin (FY26)
19.0%
Debt / equity (FY26)
0.45
OCF / EBITDA (FY26)
91.3%
OCF / EBITDA (3Y)
80.1%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Laurus Labs makes API and finished-dose generic medicines, and develops and manufactures drugs under contract for innovator pharma companies (its CDMO business), selling mostly to export markets.

Company snapshot

5thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales1,224 Cr1,195 Cr1,440 Cr1,195 Cr1,224 Cr1,415 Cr1,720 Cr1,570 Cr1,653 Cr1,778 Cr1,812 Cr2,026 Cr
Operating expenses (approx.)1,037 Cr1,014 Cr1,198 Cr1,024 Cr1,045 Cr1,130 Cr1,300 Cr1,187 Cr1,250 Cr1,298 Cr1,299 Cr1,388 Cr
EBITDA188 Cr181 Cr241 Cr171 Cr178 Cr285 Cr421 Cr382 Cr403 Cr480 Cr512 Cr638 Cr
OPM %15.3%15.2%16.8%14.3%14.6%20.2%24.4%24.3%24.4%27.0%28.3%31.5%
Other income2 Cr2 Cr19 Cr3 Cr5 Cr9 Cr59 Cr10 Cr27 Cr6 Cr12 Cr9 Cr
Interest42 Cr51 Cr51 Cr49 Cr53 Cr58 Cr56 Cr52 Cr40 Cr39 Cr40 Cr42 Cr
Depreciation93 Cr98 Cr102 Cr106 Cr108 Cr106 Cr110 Cr117 Cr120 Cr121 Cr122 Cr124 Cr
Profit before tax52 Cr33 Cr107 Cr19 Cr25 Cr133 Cr311 Cr225 Cr270 Cr325 Cr362 Cr481 Cr
Tax %28.2%28.8%29.9%33.0%20.3%30.1%25.2%28.1%28.1%22.6%22.0%24.8%
Net profit37 Cr23 Cr75 Cr13 Cr20 Cr93 Cr233 Cr162 Cr194 Cr252 Cr282 Cr362 Cr
EPS (₹)₹0.69₹0.43₹1.40₹0.23₹0.37₹1.71₹4.34₹3.02₹3.61₹4.67₹5.17₹6.81

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,932 Cr2,069 Cr2,292 Cr2,832 Cr4,814 Cr4,936 Cr6,041 Cr5,041 Cr5,554 Cr6,813 CrSign in free for the trailing twelve months
Operating expenses (approx.)1,523 Cr1,656 Cr1,936 Cr2,267 Cr3,263 Cr3,513 Cr4,448 Cr4,263 Cr4,499 Cr5,035 CrSign in free for the trailing twelve months
EBITDA408 Cr413 Cr356 Cr565 Cr1,551 Cr1,422 Cr1,592 Cr778 Cr1,055 Cr1,778 CrSign in free for the trailing twelve months
OPM %21.1%20.0%15.5%19.9%32.2%28.8%26.4%15.4%19.0%26.1%Sign in free for the trailing twelve months
Other income32 Cr29 Cr16 Cr6 Cr24 Cr15 Cr6 Cr26 Cr75 Cr55 CrSign in free for the trailing twelve months
Interest100 Cr80 Cr88 Cr90 Cr68 Cr102 Cr165 Cr183 Cr216 Cr171 CrSign in free for the trailing twelve months
Depreciation106 Cr125 Cr164 Cr187 Cr205 Cr251 Cr324 Cr385 Cr430 Cr480 CrSign in free for the trailing twelve months
Profit before tax234 Cr237 Cr120 Cr294 Cr1,301 Cr1,084 Cr1,106 Cr230 Cr488 Cr1,182 CrSign in free for the trailing twelve months
Tax %18.7%29.4%21.7%13.1%24.4%23.2%28.2%29.6%26.6%24.7%Sign in free for the trailing twelve months
Net profit190 Cr168 Cr94 Cr255 Cr984 Cr832 Cr793 Cr162 Cr358 Cr890 CrSign in free for the trailing twelve months
EPS (₹)₹20.78₹15.83₹8.83₹23.93₹18.36₹15.42₹14.69₹2.98₹6.65₹16.47Sign in free for the trailing twelve months
Dividend payout %————7.6%10.3%13.5%53.1%12.0%9.7%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital106 Cr106 Cr106 Cr107 Cr107 Cr107 Cr108 Cr108 Cr108 Cr108 Cr
Reserves1,225 Cr1,377 Cr1,452 Cr1,663 Cr2,490 Cr3,244 Cr3,930 Cr4,003 Cr4,365 Cr5,192 Cr
Borrowings769 Cr900 Cr943 Cr956 Cr1,315 Cr1,732 Cr1,972 Cr2,507 Cr2,693 Cr2,397 Cr
Other liabilities554 Cr634 Cr830 Cr1,025 Cr1,835 Cr1,877 Cr1,640 Cr1,764 Cr2,040 Cr2,682 Cr
Total liabilities2,653 Cr3,017 Cr3,331 Cr3,750 Cr5,751 Cr6,968 Cr7,660 Cr8,387 Cr9,336 Cr10,511 Cr
Fixed assets (net)1,212 Cr1,464 Cr1,607 Cr1,664 Cr1,860 Cr2,257 Cr3,016 Cr3,446 Cr3,668 Cr3,873 Cr
CWIP143 Cr163 Cr110 Cr67 Cr362 Cr813 Cr551 Cr423 Cr458 Cr773 Cr
Investments3 Cr3 Cr3 Cr46 Cr59 Cr169 Cr183 Cr302 Cr233 Cr309 Cr
Loans & advances——0.42 Cr0.49 Cr0.68 Cr0.64 Cr0.97 Cr0.95 Cr0.93 Cr0.93 Cr
Inventories509 Cr585 Cr682 Cr905 Cr1,575 Cr1,760 Cr1,685 Cr1,845 Cr1,937 Cr2,342 Cr
Trade receivables568 Cr571 Cr710 Cr791 Cr1,306 Cr1,354 Cr1,580 Cr1,663 Cr2,007 Cr2,155 Cr
Cash & bank2 Cr3 Cr3 Cr2 Cr48 Cr75 Cr46 Cr139 Cr100 Cr113 Cr
Other assets215 Cr228 Cr216 Cr274 Cr539 Cr538 Cr598 Cr567 Cr931 Cr945 Cr
Total assets2,653 Cr3,017 Cr3,331 Cr3,750 Cr5,751 Cr6,968 Cr7,660 Cr8,387 Cr9,336 Cr10,511 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity332 Cr342 Cr298 Cr347 Cr733 Cr911 Cr994 Cr666 Cr602 Cr1,624 Cr
Cash from investing-289 Cr-384 Cr-253 Cr-221 Cr-941 Cr-914 Cr-996 Cr-822 Cr-682 Cr-1,089 Cr
Cash from financing-54 Cr42 Cr-45 Cr-128 Cr255 Cr30 Cr-27 Cr250 Cr39 Cr-525 Cr
Net cash flow-10 Cr0.58 Cr0.02 Cr-1 Cr47 Cr27 Cr-30 Cr93 Cr-39 Cr13 Cr
Free cash flow (OCF − Capex)54 Cr-49 Cr43 Cr125 Cr44 Cr34 Cr4 Cr-13 Cr-39 Cr554 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %15.9%13.3%8.3%14.1%35.0%23.3%21.1%6.2%9.7%17.3%
ROE %14.3%11.3%6.0%14.4%37.8%24.6%19.5%3.9%7.8%16.4%
Debtor days1071001131029910095120132115
Inventory days182201199205243282236278290305
Days payable94107143139182141100158144163
Cash conversion cycle195194169168160242232240278257
OCF / EBITDA %81.4%82.9%83.6%61.5%47.3%64.1%62.4%85.6%57.0%91.3%
OCF / EBITDA % (3 years)——82.6%74.0%55.8%56.3%57.8%67.8%66.0%80.1%
Debt / equity0.580.610.610.540.510.520.490.610.600.45
Current ratio1.020.951.031.071.251.251.421.231.221.33
Net debt / EBITDA1.88—2.641.690.821.161.213.052.461.29